Do analysts prefer RLYB or IRD?

Opus Genetics has a consensus target price of $10.77, suggesting a potential upside of 174.73%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Opus Genetics 1 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.88

Is RLYB or IRD more profitable?

Opus Genetics has a net margin of -892.36% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Rallybio -911.07% -55.79% -51.48% Opus Genetics -892.36% -338.88% -191.21%

Do analysts prefer RLYB or AMRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, RLYB or AMRN?

Rallybio has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rallybio $860K 96.94 -$8.98M -$4.34 N/A Amarin $213.65M 1.46 -$38.80M -$0.65 N/A

Is RLYB or AMRN more profitable?

Amarin has a net margin of -15.51% compared to Rallybio's net margin of -911.07%. Amarin's return on equity of -2.99% beat Rallybio's return on equity. Company Net Margins Return on Equity Return on Assets Rallybio -911.07% -55.79% -51.48% Amarin -15.51% -2.99% -2.07%

Do analysts rate GALT or RLYB?

Galectin Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 170.94%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Galectin Therapeutics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Rallybio (RLYB) Competitors

$15.73 -0.10 (-0.63%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$15.73 0.00 (0.00%)

As of 07/10/2026 07:43 PM Eastern

Compare

RLYB vs. IRD, AMRN, LRMR, ZNTL, and GALT

Should you buy Rallybio stock or one of its competitors? MarketBeat compares Rallybio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rallybio include Opus Genetics (IRD), Amarin (AMRN), Larimar Therapeutics (LRMR), Zentalis Pharmaceuticals (ZNTL), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry.

How does Rallybio compare to Opus Genetics?

Rallybio (NASDAQ:RLYB) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 10.3% of Rallybio shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Opus Genetics has a consensus target price of $10.77, suggesting a potential upside of 174.73%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Opus Genetics had 10 more articles in the media than Rallybio. MarketBeat recorded 11 mentions for Opus Genetics and 1 mentions for Rallybio. Rallybio's average media sentiment score of 1.89 beat Opus Genetics' score of 0.29 indicating that Rallybio is being referred to more favorably in the media.

Company	Overall Sentiment
Rallybio	Very Positive
Opus Genetics	Neutral

Rallybio has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Opus Genetics has a net margin of -892.36% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-55.79%	-51.48%
Opus Genetics	-892.36%	-338.88%	-191.21%

Rallybio has higher earnings, but lower revenue than Opus Genetics. Rallybio is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	96.94	-$8.98M	-$4.34	N/A
Opus Genetics	$11.98M	27.01	-$49.59M	-$1.33	N/A

Summary

Opus Genetics beats Rallybio on 11 of the 17 factors compared between the two stocks.

How does Rallybio compare to Amarin?

Rallybio (NASDAQ:RLYB) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

In the previous week, Amarin had 2 more articles in the media than Rallybio. MarketBeat recorded 3 mentions for Amarin and 1 mentions for Rallybio. Rallybio's average media sentiment score of 1.89 beat Amarin's score of 0.40 indicating that Rallybio is being referred to more favorably in the media.

Company	Overall Sentiment
Rallybio	Very Positive
Amarin	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Rallybio has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	96.94	-$8.98M	-$4.34	N/A
Amarin	$213.65M	1.46	-$38.80M	-$0.65	N/A

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 10.3% of Rallybio shares are owned by company insiders. Comparatively, 4.2% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Amarin has a net margin of -15.51% compared to Rallybio's net margin of -911.07%. Amarin's return on equity of -2.99% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-55.79%	-51.48%
Amarin	-15.51%	-2.99%	-2.07%

Rallybio has a beta of -0.9, suggesting that its share price is 190% less volatile than the broader market. Comparatively, Amarin has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

Summary

Amarin beats Rallybio on 9 of the 15 factors compared between the two stocks.

How does Rallybio compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Larimar Therapeutics presently has a consensus price target of $12.71, indicating a potential upside of 197.06%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Larimar Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Rallybio has higher revenue and earnings than Larimar Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Rallybio	$860K	96.94	-$8.98M	-$4.34	N/A

In the previous week, Larimar Therapeutics had 10 more articles in the media than Rallybio. MarketBeat recorded 11 mentions for Larimar Therapeutics and 1 mentions for Rallybio. Rallybio's average media sentiment score of 1.89 beat Larimar Therapeutics' score of 1.07 indicating that Rallybio is being referred to more favorably in the news media.

Company	Overall Sentiment
Larimar Therapeutics	Positive
Rallybio	Very Positive

Larimar Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, suggesting that its share price is 190% less volatile than the broader market.

Larimar Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Rallybio	-911.07%	-55.79%	-51.48%

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 10.3% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Larimar Therapeutics beats Rallybio on 10 of the 16 factors compared between the two stocks.

How does Rallybio compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Zentalis Pharmaceuticals currently has a consensus price target of $5.83, indicating a potential upside of 19.54%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Zentalis Pharmaceuticals is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Zentalis Pharmaceuticals' return on equity of -53.61% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
Rallybio	-911.07%	-55.79%	-51.48%

Zentalis Pharmaceuticals has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market.

90.3% of Rallybio shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Rallybio has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Rallybio is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	5.15	-$137.06M	-$1.73	N/A
Rallybio	$860K	96.94	-$8.98M	-$4.34	N/A

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 1 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 1.89 equaled Rallybio'saverage media sentiment score.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Very Positive
Rallybio	Very Positive

Summary

Zentalis Pharmaceuticals beats Rallybio on 10 of the 14 factors compared between the two stocks.

How does Rallybio compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Galectin Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market.

In the previous week, Galectin Therapeutics and Galectin Therapeutics both had 1 articles in the media. Rallybio's average media sentiment score of 1.89 beat Galectin Therapeutics' score of 1.87 indicating that Rallybio is being referred to more favorably in the news media.

Company	Overall Sentiment
Galectin Therapeutics	Very Positive
Rallybio	Very Positive

Galectin Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 170.94%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Galectin Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Comparatively, 10.3% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Rallybio has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Rallybio	$860K	96.94	-$8.98M	-$4.34	N/A

Galectin Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Galectin Therapeutics' return on equity of 0.00% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Rallybio	-911.07%	-55.79%	-51.48%

Summary

Galectin Therapeutics beats Rallybio on 8 of the 14 factors compared between the two stocks.

Get Rallybio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLYB vs. The Competition

Export

Metric	Rallybio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$83.34M	$3.71B	$7.09B	$12.66B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-3.62	21.64	27.42	24.53
Price / Sales	96.94	323.81	528.33	96.17
Price / Cash	N/A	143.33	48.47	60.03
Price / Book	1.43	8.41	10.88	6.38
Net Income	-$8.98M	$23.85M	$3.59B	$331.87M
7 Day Performance	-0.51%	-0.75%	-0.26%	0.37%
1 Month Performance	-1.19%	8.68%	4.55%	0.59%
1 Year Performance	384.06%	55.85%	29.86%	22.26%

Rallybio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLYB Rallybio	1.0256 of 5 stars	$15.73 -0.6%	N/A	+384.1%	$83.34M	$860K	N/A	40	Positive News
IRD Opus Genetics	3.0953 of 5 stars	$4.11 +1.2%	$10.77 +162.0%	+246.9%	$335.22M	$14.20M	N/A	14
AMRN Amarin	1.6766 of 5 stars	$15.94 +0.1%	N/A	-12.1%	$333.83M	$213.65M	N/A	360	News Coverage
LRMR Larimar Therapeutics	4.3636 of 5 stars	$3.05 -4.7%	$13.17 +331.7%	+26.6%	$332.42M	N/A	N/A	30	News Coverage Positive News Insider Trade Analyst Revision
ZNTL Zentalis Pharmaceuticals	2.0407 of 5 stars	$4.85 +5.2%	$5.83 +20.3%	+266.9%	$328.17M	$67.43M	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLYB) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rallybio (RLYB) Competitors

RLYB vs. IRD, AMRN, LRMR, ZNTL, and GALT

How does Rallybio compare to Opus Genetics?

Summary

How does Rallybio compare to Amarin?

Summary

How does Rallybio compare to Larimar Therapeutics?

Summary

How does Rallybio compare to Zentalis Pharmaceuticals?

Summary

How does Rallybio compare to Galectin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB vs. The Competition

Rallybio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rallybio (RLYB) Competitors

RLYB vs. IRD, AMRN, LRMR, ZNTL, and GALT

How does Rallybio compare to Opus Genetics?

Do insiders and institutionals have more ownership in RLYB or IRD?

Do analysts prefer RLYB or IRD?

Does the media favor RLYB or IRD?

Which has more risk and volatility, RLYB or IRD?

Is RLYB or IRD more profitable?

Which has better valuation & earnings, RLYB or IRD?

Summary

How does Rallybio compare to Amarin?

Does the media favor RLYB or AMRN?

Do analysts prefer RLYB or AMRN?

Which has preferable earnings & valuation, RLYB or AMRN?

Do insiders and institutionals hold more shares of RLYB or AMRN?

Is RLYB or AMRN more profitable?

Which has more volatility & risk, RLYB or AMRN?

Summary

How does Rallybio compare to Larimar Therapeutics?

Do analysts recommend LRMR or RLYB?

Which has better earnings and valuation, LRMR or RLYB?

Does the media refer more to LRMR or RLYB?

Which has more risk & volatility, LRMR or RLYB?

Is LRMR or RLYB more profitable?

Do insiders & institutionals believe in LRMR or RLYB?

Summary

How does Rallybio compare to Zentalis Pharmaceuticals?

Do analysts prefer ZNTL or RLYB?

Is ZNTL or RLYB more profitable?

Which has more risk & volatility, ZNTL or RLYB?

Do institutionals and insiders believe in ZNTL or RLYB?

Which has higher earnings & valuation, ZNTL or RLYB?

Does the media refer more to ZNTL or RLYB?

Summary

How does Rallybio compare to Galectin Therapeutics?

Which has more volatility & risk, GALT or RLYB?

Does the media refer more to GALT or RLYB?

Do analysts rate GALT or RLYB?

Do institutionals & insiders believe in GALT or RLYB?

Which has preferable earnings and valuation, GALT or RLYB?

Is GALT or RLYB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB vs. The Competition

Rallybio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools